Inventiva out-licenses NASH candidate in Greater China

23 September 2022

Inventiva (Nasdaq: IVA), which is making solid progress with its candidate for the highly challenging non-alcoholic steatohepatitis (NASH) indication, saw its shares shoot up more than 25% to 5.06 euros yesterday, after the French biotech announced a lucrative licensing deal for its drug lanifibranor in China.

The firm has entered into a licensing and collaboration agreement with Chia Tai-Tianqing Pharmaceutical (CTTQ), a subsidiary of Sino Biopharm (1177.HK), to develop and commercialize lanifibranor, if approved in NASH and potentially other metabolic diseases, in mainland China, Hong Kong, Macau and Taiwan.

Industry analyst GlobalData has forecast that the market for NASH therapies could grow to $25 billion by 2026 across the seven major pharmaceutical markets, as new treatments come online. Currently, there are no approved drugs for the condition in major markets. The one exception is in India, where a Zydus Lifesciences (NSE: ZYDUSLIFE) unit gained clearance for its Lipaglyn (saroglitazar) in 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK